Evidence map›Paper›PMID 35693790›Full record

Trial reportFrontiers in immunology2022

Associations Between Serum Fatty Acids and Immunological Markers in Children Developing Islet Autoimmunity-The TRIGR Nested Case-Control Study.

Sari Niinistö, Maija E Miettinen, David Cuthbertson, Jarno Honkanen, Leena Hakola, Reija Autio, Iris Erlund, Petra Arohonka, Arja Vuorela, Taina Härkönen and 6 more

Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00179777 (TRIGR - Trial to Reduce IDDM in the Genetically at Risk), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00179777 nacompletednot on this map

TRIGR - Trial to Reduce IDDM in the Genetically at Risk

TypeinterventionalSponsorUniversity of HelsinkiRan2002 to 2017Enrolled5,156ConditionsDiabetes Mellitus, Type 1ArmsHydrolysed infant formula, Nonhydrolysed infant formula
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Sari NiinistöDepartment of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland.
Maija E MiettinenDepartment of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland.
David CuthbertsonHealth Informatics Institute, Morsani College of Medicine, University of South Florida, Tampa, FL, United States.
Jarno HonkanenResearch Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Leena HakolaUnit of Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland.
Reija AutioUnit of Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland.
Iris ErlundDepartment of Government Services, Finnish Institute for Health and Welfare, Helsinki, Finland.
Petra ArohonkaDepartment of Government Services, Finnish Institute for Health and Welfare, Helsinki, Finland.
Arja VuorelaResearch Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Taina HärkönenResearch Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Heikki HyötyFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Jeffrey P KrischerHealth Informatics Institute, Morsani College of Medicine, University of South Florida, Tampa, FL, United States.
Outi VaaralaResearch Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Mikael KnipPediatric Research Center, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Suvi M VirtanenDepartment of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland.
TRIGR Investigators

Funding

Trial to Reduce IDDM in the Genetically at Risk StudyU01HD040364 · NICHD · UNIVERSITY OF HELSINKI · PI KNIP, MIKAEL · 2001 to 2015
$32.7M
Trial to Reduce IDDM in the Genetically at Risk: A Nutritional primary preventionU01HD042444 · NICHD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BECKER, DOROTHY J · 2001 to 2015
$24.4M
Trial to Reduce IDDM in the Genetically at Risk (TRIGR) Data Management UnitU01HD051997 · NICHD · UNIVERSITY OF SOUTH FLORIDA · PI KRISCHER, JEFFREY P · 2006 to 2015
$7.1M
Trial to Reduce IDDM in the Genetically at Risk (TRIGR) Data Management UnitR01HD051997 · NICHD · UNIVERSITY OF SOUTH FLORIDA · PI KRISCHER, JEFFREY P · 2016 to 2018
$2.3M
Effect of early diet and virus infections on immune regulation and the development islet autoimmunity -Trial to Reduce IDDM in the Genetically at Risk (TRIGR)DP3DK106918 · NIDDK · NATIONAL INSTITUTE FOR HEALTH & WELFARE · PI VIRTANEN, SUVI MIRJAMI · 2015 to 2015
$1.1M
NICHD NIH HHS R01 HD051997NICHD NIH HHS U01 HD040364NICHD NIH HHS U01 HD042444NICHD NIH HHS U01 HD051997NIDDK NIH HHS DP3 DK106918
6 · The paper itself

Abstract

Aims: Altered immune functions as well as fatty acid intake and status have been associated with the development of type 1 diabetes. We aimed to study the relationship between fatty acids and immunological markers in young children with increased genetic risk for type 1 diabetes in order to define putative mechanisms related to development of islet autoimmunity. Methods: Serum samples for fatty acid and immunological marker measurements were obtained in the Trial to Reduce IDDM in the Genetically at Risk (TRIGR) ancillary study (Divia) from children born between 2002 and 2007 in 15 countries. Case children ( Results: Correlations between circulating fatty acids and immunological markers were different in case children who developed islet autoimmunity than in control children already at birth continuing across the first year of life. In case children, saturated fatty acids (SFAs) showed stronger correlations with immunological markers, while in controls, polyunsaturated fatty acids (PUFAs) showed stronger correlations. Conclusions: In cases, SFAs were associated with several immunological markers (CXCL10, IL-6, IL-9, IL-17, and CM-CSF) previously linked to the type 1 diabetes disease process. Findings indicate that fatty acids could have immunomodulatory potential in the early phase of the disease development, although causality between fatty acids and the immunological pathways remains to be explored. Trial registry number: NCT00179777.

Indexed as

Diabetes Mellitus, Type 1Islets of LangerhansAutoimmunityCase-Control StudiesChildChild, PreschoolFatty AcidsHumansInfantInfant, NewbornFatty Acidschemokineschildrencytokinesfatty acidsgrowth factorsimmunological markersislet autoimmunitytype 1 diabetes

Identifiers

PMID35693790
PMCPMC9175567

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.